New Products

Singleron Biotechnologies has launched Tensor, a platform that automates single-cell sequencing sample preparation from cell suspension to sequencing-ready library for up to 32 samples. Tensor, developed by Singleron in close collaboration with Hamilton Bonaduz, integrates Singleron's single-cell partitioning and library prep workflow with Hamilton's automation system.

GenomOncology has launched BioMCP, a new open-source technology that helps artificial intelligence systems access specialized medical information. BioMCP supports advanced searching and full-text retrieval from clinical trials, genetic data, and published medical research. It builds on the Model Context Protocol (MCP), an open standard created by Anthropic for connecting AI to external data sources, tools, and systems. MCP creates a common language for AI systems such as ChatGPT and Claude to access information and serves as an assistant or agent. BioMCP is freely available as open-source software but GenomOncology is currently developing a commercial version for organizations that will build on its Precision Oncology Platform. The company plans to expand BioMCP's capabilities by adding support for more medical databases, better visualization tools, and improved ability to map relationships across different information sources.

Molecular You has launched a direct-to-consumer blood testing platform in the US. Its test, which uses proteomics and metabolomics, analyzes more than 250 biomarkers in blood across metabolic, cardiovascular, cognitive, immune, and inflammatory systems and generates risk profiles for more than 26 health conditions. It also delivers personalized lifestyle, diet, and supplement recommendations. Pricing for the test starts at $1,099.

Qiagen has launched the QIAprep&amp Plasmodium Kit for malaria research and surveillance efforts. The kit combines sample preparation and qPCR into a single workflow to detect malaria-causing parasites. The assay can detect as little as one parasite per microliter, is compatible with both liquid and dried blood samples, and can be used on the Rotor-Gene Q and other platforms. Qiagen has also launched two companion assays along with the kit. The Pf/Non-Pf Detection Assay is a single-reaction screen for Plasmodium falciparum. The Pv/Pm/Po/Pk Detection Assay helps distinguish between four other species that cause malaria – P. vivax, P. malariae, P. ovale, and P. knowlesi.

LetsGetChecked has launched a comprehensive hereditary cancer test that includes in-house genetic counseling and a range of multigene panels. It identifies disease-causing variants associated with hereditary cancer syndromes across multiple organ systems including breast, ovarian, uterine, gastrointestinal, endocrine, renal, skin, and brain or nervous system cancers.

LGC Biosearch Technologies has launched several new enzymes for molecular diagnostics workflows: COD UNG, a thermolabile uracil N-glycosylase that prevents amplicon carryover contamination from prior PCR or isothermal amplifications; thermostable pyrophosphatase, a heat-tolerant enzyme for DNA polymerization reactions to improve product yield in PCR and enhanced IVT reactions; T7 exonuclease, an enzyme for NGS library prep that removes nucleotides in linear or nicked dsDNA in a stepwise fashion from 5' to 3'; and salt-tolerant endonuclease, which degrades host cell DNA and RNA in protein preparations.

Sekisui Diagnostics has launched the Metrix COVID/Flu Test for use at the point of care and at home on the Metrix Molecular Platform. The molecular test, which returns results in 20 minutes, qualitatively detects and differentiates between RNA from SARS-CoV-2, influenza A, and influenza B from anterior nares swab samples. Sekisui inked an exclusive distribution agreement with Aptitude Medical Systems last year to sell the Aptitude Metrix COVID-19 test in the US. Now that Aptitude has received clearance from the US Food and Drug Administration for the combination test, Sekisui will also offer the combination test. 

Sphere Bio has launched the Cyto-Cellect Human IgG Kappa and Viability Assay Kit, the first multiplexed assay kit developed specifically for the company's new Cyto-Mine Chroma platform. The platform uses fluorescence-based assays in picodroplets to select single cells based on secreted, surface, or intracellular markers. The kit can be used to detect secreted antibodies and assess a viability stain on the cell surface, enabling high-throughput screening of viable, high-producing clones in a single automated workflow, the company said.

Biocartis has launched its Idylla POLE-POLD1 Mutation Assay for research use only. This real-time PCR assay for the fully automated Idylla platform is designed to detect the hypermutated phenotype associated with mutations in POLE and POLD1, which encode proteins that ensure proper DNA amplification. Such mutations have been identified in endometrial and other cancers. The new assay detects 17 point mutations in the POLE gene and one mutation in the POLD1 gene, therefore covering 99 percent of the known POLE and POLD1 pathogenic mutations in a single cartridge. The test is optimized for use with formalin-fixed, paraffin-embedded tissue specimens. It has a hands-on time of under three minutes and a turnaround time of approximately 95 minutes, Biocartis said.

Breakthrough Genomics has launched a literature database covering more than 10 million genetic variants linked with detailed variant-patient information, functional studies, disease segregation data, and more. The new database has been integrated into the company's AI-powered genomic analysis platform Virtual Geneticist. It is designed to streamline and automate genetic variant classification for clinical reporting. The company said the new database automates American College of Medical Genetics and Genomics variant classification, saving geneticists and clinical labs time during the variant interpretation process.